Class / Patent application number | Description | Number of patent applications / Date published |
514255040 | Plural carbocyclic rings bonded directly to the same acyclic carbon atom which is attached directly or indirectly to the piperazine ring by nonionic bonding | 66 |
20080214572 | Selected Tetracyclic Tetrahydrofuran Derivatives Containing a Cyclic Amine Side Chain - This invention concerns novel tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain with binding affinities towards serotonin receptors, in particular 5-HT | 09-04-2008 |
20080287459 | Pharmaceutical Composition for Treating Hair Loss and Benign Prostatic Hyperplasia - The present invention is related to an orally administered pharmaceutical composition for the prevention of hair loss; having the effects of epilation, hair toning, and hair growth; and for the treatment of female hirsutism and benign prostatic hyperplasia. The composition of the present invention is non-steroidal and is advantageous in that it has no side effects such as lowering of sexual function, etc. shown in the conventional oral treatment agents of related diseases. | 11-20-2008 |
20080300262 | Combination Therapy for Relief of Pain - The present invention relates to analgesic compositions comprising a non-peptidyl N-type calcium channel blocker, and at least one other analgesic compound, and to methods of using N-type calcium channel blockers in combination with at least one other pain-relieving compound that alleviates pain through a mechanism other than N-type calcium channel blockage, or with a non-pharmacological therapeutic protocol. | 12-04-2008 |
20080306090 | THIOUREA DERIVATIVES - Thiourea compounds of the following formula: | 12-11-2008 |
20090036469 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS - The present invention is directed to a compound of formula (I), | 02-05-2009 |
20090048268 | ANTI-HISTAMINE COMPOSITIONS AND USE THEREOF - The present invention provides for a storage stable pharmaceutical liquid solution for oral administration having a pharmaceutically effective amount of an antihistamine and having a purity equal to or greater than about 99% by weight-based HPLC assay, residual solvents of less than about 0.5%, and a total impurity of less than about 0.2%. The storage stable solution preferably contains cetirizine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid solution as well as a method of treating a mammal with a therapeutically effective amount of cetirizine in the stable pharmaceutical liquid solution. | 02-19-2009 |
20090062305 | DEUTERIUM-ENRICHED CETIRIZINE - The present application describes deuterium-enriched cetirizine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
20090082364 | DEUTERIUM-ENRICHED LEVOCEDTIRIZINE - The present application describes deuterium-enriched levocetirizine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090105276 | LINDANE LOTION AND METHODS - The present invention is directed to methods of treatment for scabies using different concentrations of lindane lotions for varying contact times. Compositions of low concentration lindane lotions are also included. | 04-23-2009 |
20090111833 | Injectable meclizine formulations and methods - Methods of treating or preventing a vertigo, nausea, or vomiting condition comprising injecting a subject with a pharmaceutically acceptable formulation consisting essentially of an effective amount of meclizine or a pharmaceutically acceptable salt thereof, a chemically modified cyclodextrin, and an aqueous carrier medium having a pH between about 2 and about 7 are disclosed. An injectable pharmaceutical formulation for treating or preventing a vertigo, nausea, or vomiting condition consisting essentially of an effective amount of meclizine, a chemically modified cyclodextrin, and an aqueous carrier medium having a pH between about 2 and about 7 is also disclosed. | 04-30-2009 |
20090176804 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS - The present invention is directed to 2-phenyl-indole compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, eczema, urticaria diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like. | 07-09-2009 |
20090291966 | Method Of Treating Anxious Major Depressive Disorder - The invention is directed to using 4-{(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-N,N-diethylbenzamide, or enantiomer thereof, or pharmaceutically acceptable salt thereof, and/or mixture thereof to treat anxious major depressive disorder (AMDD). | 11-26-2009 |
20090298852 | Pellet-form slow-release preparation for vertigo - The invention describes a pharmaceutical composition of a slow-release preparation in the form of pellets for the treatment of vertigo of any genesis. Thus, a pharmaceutical composition is described that contains cinnarizine and dimenhydrinate, wherein the release of active ingredients is slowed down and the preparation is in the form of pellets. In addition, the pharmaceutical composition contains binding agent, slow-release agent and fillers. | 12-03-2009 |
20100069402 | Treatment of Behavioral Disorders - The present invention relates to a method for treating a behavior disorder comprising the administration of a therapeutically effective amount of antihistamine, such as cetirizine, fexofenadine; loratadine, and desloratadine. The behavioral disorders may include ADHD, anxiety, depression, and autism. The method may include the administration of the antihistamine in combination with a stimulant medication, such as methylphenidate, thereby to achieve a synergistic effect. In any event, the amount of antihistamine and/or stimulant is effective to downregulate neurotrophic factors such as nerve growth factor or CD40. The invention is also directed to a method of preventing the onset of behavior disorders in patients presenting with symptoms of allergic rhinitis. | 03-18-2010 |
20100069403 | Methods for preventing or treating cardiac arrhythmia - Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof. | 03-18-2010 |
20100113478 | INDOLONE MODULATORS OF 5-HT3 RECEPTOR - The present invention relates to new indolone modulators of 5-HT3 receptor, pharmaceutical compositions thereof, and methods of use thereof. | 05-06-2010 |
20100152201 | Oligomer-Antihistamine Conjugates - The invention provides antihistamine drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the antihistamine drug not attached to the water-soluble oligomer. | 06-17-2010 |
20100168130 | Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof - Compounds of general formula: | 07-01-2010 |
20100222364 | PHARMACEUTICAL COMPOSITION FOR TREATING HAIR LOSS AND BENIGN PROSTATIC HYPERPLASIA - Disclosed is the use of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid or its pharmaceutically acceptable salt for the prevention of hair loss; for hair regrowth, hair toning and hair growth; and for the treatment of female hirsutism and benign prostatic hyperplasia. | 09-02-2010 |
20100280047 | SALTS OF ACTIVE INGREDIENTS WITH POLYMERIC COUNTER-IONS - Polymeric water-soluble salts of medicaments that are sparingly soluble in water, consisting of a polymer with anion character that is soluble in water at pH values of 2-13 and a sparingly soluble medicament with cation character. | 11-04-2010 |
20100292251 | MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF - The invention relates to Benzhydryl piperazine salts of [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid represented by the formula (III). Furthermore, the invention relates to the use of Benzhydryl piperazine salts of [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid represented by the formula (III) for the preparation of substantially pure [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropane acetic acid or its alkali salts and pharmaceutical composition comprising the same. | 11-18-2010 |
20110015209 | Sigma ligands for neuronal regeneration and functional recovery - The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by multiple sclerosis. In other methods, the sigma receptor ligands are administered after MS to facilitate functional recovery. The administration of the sigma receptor ligands causes fasted functional recovery. | 01-20-2011 |
20110034480 | COMPOSITIONS COMPRISING CETIRIZINE AND A NON BETA-2-ADRENORECEPTOR AGONIST, A BETA-2-ADRENORECEPTOR AGONIST OR AN ANTI-INFLAMMATORY AND THE USE THEREOF FOR THE TREATMENT OF RESPIRATORY DISORDERS - There is described a pharmaceutical composition comprising a therapeutically effective amount of cetirizine, or a pharmaceutically acceptable derivative thereof, and a therapeutically effective amount of one or more compounds selected from the group consisting of a non beta-2-adrenoreceptor agonist; a beta-2-adrenoreceptor agonist and an anti-inflammatory agent; in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. | 02-10-2011 |
20110207745 | SOLID FORMS OF 4--N,N-DIETHYLBENZAMIDE, COMPOSITIONS THEREOF, AND USES THEREWITH - Solid forms comprising salts of 4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-N,N-diethylbenzamide, compositions comprising the solid forms, methods of making the solid forms, and methods of their use for the treatment of various diseases and/or disorders are provided herein. | 08-25-2011 |
20110230496 | NOVEL PROCESS FOR PREPARING HIGHLY PURE LEVOCETIRIZINE AND SALTS THEREOF - A process for preparing pure levocetirizine and salts thereof, e.g., the levocetirizine dihydrochloride, and a pharmaceutical composition comprising levocetirizine dihydrochloride produced by the process are disclosed. | 09-22-2011 |
20110237604 | METHODS FOR PREVENTING OR TREATING CARDIAC ARRHYTHMIA - Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof. | 09-29-2011 |
20110281892 | METHOD AND FORMULATION FOR COLD TREATMENT IN ADULTS AND CHILDREN WITH INCREASED SAFETY - Methods and dosage formulations for the safe treatment of cold, cough, flu, and sinus symptoms in children and adolescents by age and nature of symptoms, and adults and the elderly by age, nature of symptoms, and concomitant patient medical conditions. The method of the present invention comprises the formulation of a cold medication which consists essentially of combinations of a nonsedating or minimally sedating antihistamines with pain relievers and the expectorant, guaifenesin. | 11-17-2011 |
20120004242 | Oligomer-Diarylpiperazine Conjugates - The invention relates to (among other things) oligomer-diarylpiperazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated diarylpiperazine compounds. | 01-05-2012 |
20120010216 | Pharmaceutical compositions containing vanoxerine - Disclosed embodiments are related to compositions of vanoxerine (GBR 12909), including compositions of vanoxerine and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof. | 01-12-2012 |
20120010217 | NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF - Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute urticaria or angioedema associated with an acute allergic reaction are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms with the same number of mg of cetirizine. | 01-12-2012 |
20120010218 | FORMULATIONS - The present invention relates to pharmaceutical compositions for oral administration of active compounds. | 01-12-2012 |
20120028992 | Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals - Disclosed are pharmaceutical compositions for and methods of preventing or treating acute and/or chronic cardiac arrhythmias in a mammal, including terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm, which contain a combination of 1-[2-[(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine. | 02-02-2012 |
20120028993 | Compounds Effective Against Cancer - The present invention describes a Composition, comprising one or more compounds selected from the group consisting of a) compound (I) which is ethacrynic acid bezafibrate, fenofibrate, and/or griseofulvin, b) compound (II), which is ciclopirox ciclopirox olamine, octopirox, and/or cinnarizine, c) mixtures of compound (I) and compound (II), or pharmaceutically acceptable derivatives thereof for the treatment of cancer. The present invention is further directed to the use of said compounds or a mixture of compounds for the manufacture of a medicament for the treatment of cancer and to the use of said compound in a method for treating cancers in animals and humans. | 02-02-2012 |
20120108608 | INJECTABLE MECLIZINE FORMULATIONS AND METHODS - Methods of treating or preventing a vertigo, nausea, or vomiting condition comprising injecting a subject with a pharmaceutically acceptable formulation consisting essentially of an effective amount of meclizine or a pharmaceutically acceptable salt thereof, a chemically modified cyclodextrin, and an aqueous carrier medium having a pH between about 2 and about 7 are disclosed. An injectable pharmaceutical formulation for treating or preventing a vertigo, nausea, or vomiting condition consisting essentially of an effective amount of meclizine, a chemically modified cyclodextrin, and an aqueous carrier medium having a pH between about 2 and about 7 is also disclosed. | 05-03-2012 |
20120136007 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS - Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries. | 05-31-2012 |
20120142704 | PHARMACEUTICAL SOLUTION OF CETIRIZINE HYDROCHLORIDE - A pharmaceutical solution comprising cetirizine hydrochloride, an alcohol compound with less than 3 carbon atoms, a preservative and urea is disclosed. The cetirizine hydrochloride is in racemic form or in levo form. | 06-07-2012 |
20120149717 | Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof - Compounds of general formula: | 06-14-2012 |
20120157474 | Methods of Identifying and Using General or Alternative Splicing Inhibitors - The present invention is based on the discovery of a cell-based system to identify novel modulators of splicing or splicing dependent processes. The cell-based system of the present invention utilizes a fast and highly sensitive reporter, that responds to defects in the splicing machinery itself and is sensitive to changes in the signals that regulate splicing dependent processes such as those that modulate the EJC, splicing-dependent export, localization or translation efficiency. The present invention further uses the cell-based screen to identify several small molecules that modulate both constitutive and alternative splicing. Accordingly, the present invention includes general or alternative splicing inhibitors identified using the assay described herein. The present invention also provides methods of treating a subject having a condition associated with aberrant target RNA expression. The present invention further details a kit that may be directed to specifically detecting a general or alternative splicing inhibitor of the invention. | 06-21-2012 |
20120157475 | Combination Preparation Against Vertigo - The use of cinnarizine and dimenhydrinate or their physiologically compatible salts in combination is described for the treatment of vertigo of any genesis. | 06-21-2012 |
20120178763 | Method of Treating Anxious Major Depressive Disorder - The invention is directed to using 4-{(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-N,N-diethylbenzamide, or enantiomer thereof, or pharmaceutically acceptable salt thereof, and/or mixture thereof to treat anxious major depressive disorder (AMDD). | 07-12-2012 |
20120190691 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES - The present invention relates to pharmaceutical composition comprising a CRTH2 antagonist and at least one histamine receptor antagonist, medicaments containing said pharmaceutical compositions, and the use of said pharmaceutical compositions for treating respiratory and inflammatory diseases and conditions. | 07-26-2012 |
20120277250 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention relates to compounds of formula I: | 11-01-2012 |
20130005740 | PROCESS FOR PREPARATION OF OVER-THE-COUNTER GELATIN OR PECTIN-BASED DRUG DELIVERY - Disclosed herein is a process producing a therapeutic comestible gummie product, the process comprises providing a sugar and/or sugar alcohol, water and heating to at least 80° C. to produce a first mixture. A gelling agent and water is also provided and heat to at least 80° C. to produce a second mixture. Combining the first and second mixtures to produce a slurry. The slurry is heated to at least 112° C. to produce a gummie base. The gummie base is cooled to an optimal temperature of below 90° C. for the addition of an active drug and the active drug is substantially uniformly mixed with the gummie base. In some embodiments the active is drug is mixed with an ingestible oil and added to the cooling slurry. The gummie base and active drug mixture is then poured into molding trays and allowed to cure. Also disclosed herein by way the process of the present disclosure is therapeutic comestible gummie product. Furthermore, the present disclosure comprises a therapeutic comestible gummie product comprising ibuprofen and/or other active drug(s). | 01-03-2013 |
20130005741 | SUBSTITUTED PYRIMIDINE AS A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST - The present invention is directed to a 2,6-substituted-4-monosubstitutedamino-pyrimidine compound of formula (I): | 01-03-2013 |
20130030009 | METHOD FOR THE TREATMENT AND/OR PREVENTION OF ORAL ALLERGIC SYMPTIONS OF THE LIPS DUE TO ORAL CONTACT WITH A FOOD ALLERGEN - A method of applying a topical preparation of at least one of a mast cell stabilizer, an antihistamine, and a leukotriene inhibitor is disclosed for prevention and/or treatment of oral allergy syndrome of the lips, including lip itchiness and/or swelling. For example, topical application of Cromolyn Sodium to the lips can be used to prevent and/or treat allergic reaction to consumption or other contact with raw fruits and/or raw vegetables. The topical administration can be performed by using applicator devices that apply at least one of a mast cell stabilizer and an antihistamine in the form of a liquid, or a gel, or a butter, or a wax-like solid, or a liposome suspension. Applicator devices can include at least one of: a roller, a brush, a sponge, a swab, a tube, a lipstick. The taste of the at least one of a mast cell stabilizer and an antihistamine can be masked by flavors. | 01-31-2013 |
20130030010 | NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF - Disclosed are injectable formulations of cetirizine for treating acute allergic reactions and methods for treating acute allergic reactions. In particular, an intravenous injectable is disclosed as are methods of treating acute allergic reactions. | 01-31-2013 |
20130053399 | METHODS OF ADMINISTERING ANTIHISTAMINES - Methods of using combinations of antihistamines by administering an attenuated dosage amount of a first generation antihistamine for a quick onset concomitantly with a maintenance dosage amount of a second or third generation antihistamine are disclosed. | 02-28-2013 |
20130053400 | OLIGOMER-ANTIHISTAMINE CONJUGATES - The invention provides antihistamine drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the antihistamine drug not attached to the water-soluble oligomer. | 02-28-2013 |
20130065910 | ORAL MECLIZINE AQUEOUS FORMULATIONS WITH TASTE FLAVORING AGENT - An oral meclizine aqueous formulation is disclosed. The oral meclizine aqueous formulation comprises a solubizier for enhancing aqueous solubility of meclizine, and a taster flavoring agent selected from the group consisting of sugar, sucrose, sorbitol, sucralose, saccharin sodium, sodium cyclamate, aspartame, neotame, acesulfame potassium, stevioside, and their mixtures. Preferably the solubilizer is hydroxypropyl-β-cyclodextrin or polyethylene glycol 660 13-hydroxystearate. The oral meclizine aqueous formulation can provide a rapid onset of therapeutic effects of meclizine. | 03-14-2013 |
20130210835 | PHARMACEUTICAL COMPOSITIONS - A composition of an antitussive, a decongestant, or an antihistamine to treat respiratory and oral pharyngeal congestion and related symptoms in a patient. | 08-15-2013 |
20130252971 | Ophthalmic Formulations of Cetirizine and Methods of Use - The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye. | 09-26-2013 |
20130303546 | NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF - Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute urticaria or angioedema associated with an acute allergic reaction are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms with the same number of mg of cetirizine. | 11-14-2013 |
20140155412 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES - The invention relates to (among other things) oligomer-diarylpiperazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated diarylpiperazine compounds. | 06-05-2014 |
20140275116 | PRODUCT AND METHOD FOR TREATING DIARRHEA - A method of treating diarrhea in a patient includes administering an H1 receptor antagonist and an H2 receptor antagonist to the patient. | 09-18-2014 |
20140329835 | DOSAGE FORM FOR INSERTION INTO THE MOUTH - Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract. | 11-06-2014 |
20150072996 | FORMULATIONS AND METHODS FOR TREATMENT OF WOUNDS AND INFLAMMATORY SKIN CONDITIONS - The disclosure of the present application includes topically administrable compositions and methods for treating wounds and inflammatory conditions of the skin in mammals. In an exemplary embodiment, the composition includes a therapeutic amount of antihistamine selected from the group consisting of a non-sedating antihistamine, a physiologically acceptable acid of a non-sedating antihistamine, a salt of a non-sedating antihistamine, an amide of a non-sedating antihistamine, and a combination of two or more of these; a therapeutic amount of creatine; a therapeutic amount of creatinine; and emu oil product selected from the group consisting of emu oil, a biologically active fraction of emu oil, and a combination of these. The combination of non-sedating antihistamine, creatine, and creatinine with emu oil has been found to produce a synergistic effect that is more effective in the treatment of skin wounds than the compounds used separately. | 03-12-2015 |
20150290188 | PHARMACEUTICAL COMPOSITIONS CONTAINING ENANTIOMERICALLY PURE AND/OR RACEMIC MIXTURES OF CHIRAL PIPERAZINE COMPOUNDS AND METHODS OF TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA, RESTORING NORMAL SINUS RHYTHM, PREVENTING RECURRENCE OF CARDIAC ARRHYTHMIA AND MAINTAINING NORMAL SINUS RHYTHM IN MAMMALS THROUGH ADMINISTRATION OF SAID COMPOSITIONS - Disclosed embodiments are related to compositions of a chiral piperazine compounds including compositions comprising enantiomerically pure or racemic mixtures of said piperazine compounds, and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof. | 10-15-2015 |
20150307457 | GLYCINE TRANSPORTER-1 INHIBITORS - The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. | 10-29-2015 |
20150335640 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES - The invention relates to (among other things) oligomer-diarylpiperazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated diarylpiperazine compounds. | 11-26-2015 |
20150336917 | NOVEL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS OF TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA, RESTORING NORMAL SINUS RHYTHM, PREVENTING RECURRENCE OF CARDIAC ARRHYTHMIA AND MAINTAINING NORMAL SINUS RHYTHM IN MAMMALS - Novel piperazine compounds are disclosed. Also disclosed are pharmaceutical compositions containing these compounds and therapeutic methods of treating cardiac arrhythmias in mammals, particularly humans, including terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm using these compounds. | 11-26-2015 |
20150343067 | Monolithic Dosage Form for the Modified Release of an Active Ingredient Combination - The invention relates to a monolithic peroral dosage form which allows a modified release, preferably an extended and delayed release, of an active ingredient combination of active ingredients with solubility properties that strongly deviate from one another. The dosage form comprises at least one emulsifier with a polyalkylene oxide structural motif and at least one controlled-release agent. Using the dosage forms according to the invention, even active ingredients which have a limited storage stability and other unfavorable active ingredient properties that additionally hinder processing can be featured in an optimal manner. The invention also relates to a method for producing the dosage form and to the use thereof. | 12-03-2015 |
20160038482 | VANOXERINE FOR SELF-ADMINISTRATION FOR TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA IN MAMMALS - Methods of administration of vanoxerine wherein a patient, previously and successfully treated for cardiac arrhythmia with vanoxerine is prescribed a further dose for self-administration of a further dose of vanoxerine for treatment of a subsequent occurrence of cardiac arrhythmia. | 02-11-2016 |
20160051541 | PHARMACEUTICAL COMPOSITIONS COMPRISING VANOXERINE AND ANTIANGINAL COMPOUNDS, AND METHODS OF ADMINISTRATION OF THE SAME FOR TREATING EPISODES OF CARDIAC ARRHYTHMIA, MAINTAINING NORMAL SINUS RHYTHM, PREVENTING RECURRENCE OF CARDIAC ARRHYTHMIA, AND TREATMENT OF CHRONIC CARDIAC ARRHYTHMIA IN MAMMALS - Disclosed embodiments are related to pharmaceutical compositions comprising vanoxerine and an antianginal compound and methods of administration of vanoxerine and an antianginal composition to maintain steady state pharmacological concentration levels in a mammal. | 02-25-2016 |
20160051542 | METHODS OF ADMINISTRATION OF SINGLE DOSES OF VANOXERINE TO TERMINATE ACUTE EPISODES OF CARDIAC ARRHYTHMIA - Compositions and methods of treating patients suffering from symptoms of recent onset atrial fibrillation or atrial flutter comprising administration of a single dose of about 200 to about 400 mg of vanoxerine to return said patient to normal sinus rhythm in less than about 24 hours. | 02-25-2016 |
20160051543 | METHODS OF TREATMENT OF CARDIAC ARRHYTHMIAS USING VANOXERINE AND MODIFICATION OF DIET - Disclosed embodiments are related to methods of treatment of cardiac arrhythmias comprising administration of vanoxerine (GBR 12909) in connection with food of a predetermined fat content to modulate the plasma level concentrations of vanoxerine in a patient. | 02-25-2016 |
20160120811 | METHODS OF ADMINISTERING ANTIHISTAMINES - Methods of using combinations of antihistamines by administering an attenuated dosage amount of a first generation antihistamine for a quick onset concomitantly with a maintenance dosage amount of a second or third generation antihistamine are disclosed. | 05-05-2016 |